Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Genitourinary 1Gastrointestinal 1

Conditions

Lung Neoplasms 2Urinary Bladder Neoplasms 1Terminal Cancer 1Solid Tumor 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Postoperative Cognitive Complications 1Polyps 1Patient Satisfaction 1Pancreatitis 1Pancreatic Neoplasms 1Pain, Postoperative 1Pain 1Mouth Neoplasms 1Gastrointestinal Stromal Tumors 1Fractures, Bone 1Colonic Neoplasms 1Choledocholithiasis 1Choledochal Cyst 1Cholangiocarcinoma 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Anxiety Disorders 1

Interventions

nilotinib 2Sunitinib 2Imatinib Mesylate 2regorafenib 1avapritinib 1Oxaliplatin 1Midazolam 1Lead 1Esomeprazole 1Erlotinib Hydrochloride 1Caffeine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Gastrointestinal Stromal Tumors × Midazolam × Clear all
NCT01402089 2016-02-02

Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients

Cantonal Hospital of St. Gallen

Phase 4 Completed
54 enrolled
GastrointestinalGenitourinarySarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Lung Neoplasms, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡